GERON CORP Increase (Decrease) in Employee Related Liabilities
GERON CORP (GERN) reported Increase (Decrease) in Employee Related Liabilities of -$21.39 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities · last filed 2026-08-05
- GERON CORP increase (decrease) in employee related liabilities for the quarter ending 2026-06-30 was -$382.00K, a 122.04% decline year-over-year.
- GERON CORP increase (decrease) in employee related liabilities for the quarter ending 2026-03-31 was -$21.01M.
- GERON CORP increase (decrease) in employee related liabilities for the quarter ending 2025-06-30 was $1.73M.
- GERON CORP increase (decrease) in employee related liabilities for the quarter ending 2025-03-31 was -$13.20M.
- GERON CORP increase (decrease) in employee related liabilities for fiscal 2025 was $7.69M, a 15.03% decline from fiscal 2024.
- GERON CORP increase (decrease) in employee related liabilities for fiscal 2024 was $9.05M, a 306.88% increase from fiscal 2023.
- GERON CORP increase (decrease) in employee related liabilities for fiscal 2023 was $2.22M, a 35.25% decline from fiscal 2022.
- GERON CORP increase (decrease) in employee related liabilities for fiscal 2022 was $3.44M.
| Period end | Increase (Decrease) in Employee Related Liabilities 3 month | Increase (Decrease) in Employee Related Liabilities 6 month | Increase (Decrease) in Employee Related Liabilities 12 month | Increase (Decrease) in Employee Related Liabilities 12 month as first filed |
|---|---|---|---|---|
| 2026-06-30 | -$382.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$21.39M 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | -$21.01M 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $7.69M 10-K · filed 2026-03-02 | |||
| 2025-06-30 | $1.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$11.47M 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | -$13.20M 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | $9.05M 10-K · filed 2026-03-02 | |||
| 2023-12-31 | $2.22M 10-K · filed 2026-03-02 | |||
| 2022-12-31 | $3.44M 10-K · filed 2025-02-27 | |||
| 2021-12-31 | -$119.00K 10-K · filed 2024-02-28 | |||
| 2020-12-31 | $3.39M 10-K · filed 2023-03-16 | |||
| 2019-12-31 | $2.19M 10-K · filed 2022-03-10 | |||
| 2018-12-31 | -$743.00K 10-K · filed 2021-03-11 | |||
| 2017-12-31 | $542.00K 10-K · filed 2020-03-12 | |||
| 2016-12-31 | -$183.00K 10-K · filed 2019-03-07 | |||
| 2015-12-31 | -$1.19M 10-K · filed 2018-03-16 | -$1.24M 10-K · filed 2016-03-10 | ||
| 2014-12-31 | $486.00K 10-K · filed 2017-03-01 | $580.00K 10-K · filed 2015-03-11 | ||
| 2013-12-31 | -$431.00K 10-K · filed 2016-03-10 | |||
| 2012-12-31 | $3.55M 10-K · filed 2015-03-11 | |||
| 2011-12-31 | $944.00K 10-K · filed 2014-03-17 | |||
| 2010-12-31 | $5.40M 10-K · filed 2013-03-15 | |||
| 2009-12-31 | $4.17M 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |